NRBO - NeuroBo Pharmaceuticals Inc Stock Price, Fair Value and News

4.66+0.06 (+1.30%)Market Closed

Market Summary

4.66+0.06

Market Closed

1.30%

NRBO Stock Price

View Fullscreen

NRBO RSI Chart

NRBO Valuation

Market Cap

23.1M

Price/Earnings (Trailing)

-1.39

EV/EBITDA

-0.45

Price/Free Cashflow

-1.57

MarketCap/EBT

-1.39

NRBO Price/Sales (Trailing)

NRBO Profitability

Return on Equity

-164.41%

Return on Assets

-97.34%

Free Cashflow Yield

-63.76%

NRBO Fundamentals

NRBO Earnings

Earnings (TTM)

-16.6M

Earnings Growth (Yr)

-157.3%

Earnings Growth (Qtr)

-26.08%

Breaking Down NRBO Revenue

Last 7 days

18.7%

Last 30 days

35.8%

Last 90 days

-10.8%

Trailing 12 Months

-2.7%

How does NRBO drawdown profile look like?

NRBO Financial Health

Current Ratio

2.46

NRBO Investor Care

Shares Dilution (1Y)

44.07%

Diluted EPS (TTM)

-3.26

Tracking the Latest Insider Buys and Sells of NeuroBo Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 01, 2024	woodworth marshall h	acquired	-	-	33,496	chief financial officer
Dec 01, 2023	tursi james patrick	acquired	-	-	32,157	-
Aug 11, 2023	kim hyung heon	acquired	-	-	625,064	ceo & president
Jul 27, 2023	strickland d gordon	acquired	-	-	100,000	-
Jul 27, 2023	salsbury michael	acquired	-	-	100,000	-
Jul 27, 2023	kim na yeon	acquired	-	-	100,000	-
Jul 27, 2023	groves jason l	acquired	-	-	100,000	-
Jul 27, 2023	glickman mark a	acquired	-	-	37,500	-
Jul 27, 2023	koven andrew i	acquired	-	-	100,000	-
Jul 26, 2022	e&investment, inc.	sold	-	-	-1,445,270	-

Which funds bought or sold NRBO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	unchanged	-	1.00	8.00	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-23.44	-1,221	6,761	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-	4.00	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	10.00	102	-%
May 15, 2024	STATE STREET CORP	new	-	63,939	63,939	-%
May 15, 2024	Hudson Bay Capital Management LP	sold off	-100	-153,748	-	-%
May 14, 2024	NORTHERN TRUST CORP	new	-	55,248	55,248	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	19.45	20,725	84,702	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	unchanged	-	10.00	102	-%
May 10, 2024	JPMORGAN CHASE & CO	new	-	33.00	33.00	-%

Are Funds Buying or Selling NRBO?

Are funds buying NRBO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NRBO

No. of Funds

Unveiling NeuroBo Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 28, 2023	strategic risk, llc.	6.3%	1	SC 13G
Feb 14, 2023	altium capital management lp	0%	0	SC 13G/A
Dec 30, 2022	dong-a st co., ltd	65.5%	12,429,353	SC 13D/A
Nov 17, 2022	altium capital management lp	7.7%	312,430	SC 13G
Nov 10, 2022	dong-a st co., ltd	2.4%	96,020	SC 13D/A
Sep 23, 2022	jk biopharma solutions, inc	0.0%	0	SC 13D/A
Sep 16, 2022	dong-a st co., ltd	10.7%	96,020	SC 13D/A
Nov 10, 2021	jk biopharma solutions, inc	6.8%	1,817,842	SC 13D/A
Sep 01, 2021	dong-a st co., ltd	12.9%	2,880,612	SC 13D/A
Aug 30, 2021	dong-a st co., ltd	12.9%	2,880,612	SC 13D/A

Recent SEC filings of NeuroBo Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 30, 2024	8-K	Current Report
Apr 30, 2024	ARS	ARS
Apr 30, 2024	DEF 14A	DEF 14A
Apr 23, 2024	EFFECT	EFFECT
Apr 17, 2024	8-K	Current Report
Apr 16, 2024	8-K	Current Report
Apr 12, 2024	S-3	S-3
Apr 01, 2024	8-K	Current Report

Peers (Alternatives to NeuroBo Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

NeuroBo Pharmaceuticals Inc News

Latest updates

NeuroBo Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-25.3%	17.00	23.00	26.00	29.00	31.00	34.00	8.00	10.00	13.00	17.00	8.00	11.00	14.00	11.00	13.00	16.00	12.00	14.00	2.00	4.00	6.00
Current Assets	-25.5%	17.00	23.00	26.00	29.00	31.00	34.00	8.00	10.00	13.00	17.00	8.00	10.00	14.00	11.00	13.00	15.00	11.00	14.00	2.00	4.00	6.00
Cash Equivalents	-28.7%	16.00	22.00	26.00	29.00	31.00	33.00	6.00	9.00	12.00	16.00	7.00	10.00	13.00	10.00	12.00	14.00	10.00	14.00	21.00	25.00	2.00
Net PPE	2.2%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-
Liabilities	13.9%	7.00	6.00	5.00	4.00	11.00	12.00	2.00	1.00	2.00	2.00	2.00	1.00	1.00	4.00	4.00	3.00	4.00	2.00	3.00	2.00	2.00
Current Liabilities	14.5%	7.00	6.00	5.00	4.00	11.00	12.00	2.00	1.00	1.00	2.00	2.00	1.00	1.00	4.00	4.00	3.00	4.00	2.00	3.00	2.00	2.00
Shareholder's Equity	-39.6%	10.00	17.00	22.00	25.00	21.00	22.00	6.00	9.00	12.00	15.00	6.00	9.00	13.00	7.00	10.00	12.00	8.00	12.00	-	2.00	4.00
Retained Earnings	-6.2%	-115	-108	-102	-99.10	-98.40	-95.79	-91.12	-88.01	-84.70	-81.83	-77.25	-73.80	-69.87	-66.54	-47.03	-43.98	-41.60	-36.87	-94.26	-90.83	-87.91
Additional Paid-In Capital	0.1%	125	125	124	124	119	118	97.00	97.00	97.00	96.00	83.00	83.00	83.00	74.00	57.00	56.00	49.00	49.00	93.00	93.00	92.00
Shares Outstanding	0%	5.00	5.00	5.00	5.00	3.00	3.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-
Float	-	-	-	-	7.00	-	-	-	7.00	-	-	-	31.00	-	-	-	23.00	-	-	-	10.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-88.6%	-6,400	-3,393	-2,814	-2,045	-2,547	-1,807	-2,359	-2,717	-4,829	-2,899	-2,507	-3,587	-6,141	-2,348	-1,954	-2,324	-4,138	-1,278	-3,345	-1,192	-1,224
Share Based Compensation	5.0%	105	100	172	24.00	-74.00	218	218	211	207	188	107	180	187	160	209	171	159	-75.00	54.00	79.00	60.00
Cashflow From Investing	44.4%	-5.00	-9.00	-37.00	-	-4.00	-	-	-	-	-583	-	-	-	71.00	-	-	-2.00	-5,939	-93.00	-	-
Cashflow From Financing	-	-	-	-	-	-	28,815	-	-	-	12,886	-24.00	72.00	9,092	-	-	6,805	53.00	1.00	-9.00	34,434	-10,259

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NRBO Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 4,904	$ 637
General and administrative	1,977	1,883
Total operating expenses	6,881	2,520
Loss from operations	(6,881)	(2,520)
Other income (expense):
Change in fair value of warrant liabilities	(70)	(84)
Interest income	237
Total other income	167	(84)
Loss before income taxes	(6,714)	(2,604)
Provision for income taxes	0	0
Net loss	(6,714)	(2,604)
Comprehensive loss	$ (6,714)	$ (2,604)
Loss per share:
Net loss per share, basic	$ (1.32)	$ (0.51)
Net loss per share, diluted	$ (1.32)	$ (0.51)
Weighted average shares of common stock outstanding:
Basic (in shares)	5,089,408	5,059,003
Diluted (in shares)	5,089,408	5,059,003

NRBO Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash	$ 15,988	$ 22,435
Prepaid expenses and other current assets	776	77
Total current assets	16,764	22,512
Property and equipment, net	47	46
Right-of-use asset	186	202
Other assets	21	21
Total assets	17,018	22,781
Current liabilities:
Accounts payable (including related party payable of $794 and $0 as of March 31, 2024 and December 31, 2023, respectively)	2,079	821
Accrued liabilities (including related party payable of $175 and $789 as of March 31, 2024 and December 31, 2023, respectively)	3,948	4,414
Warrant liabilities	728	658
Lease liability, short-term	70	67
Total current liabilities	6,825	5,960
Lease liability, long-term	117	136
Total liabilities	6,942	6,096
Commitments and contingencies (Note 4)
Stockholders' equity
Preferred stock, $0.001 par value per share; 10,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued or outstanding as of March 31, 2024 and December 31, 2023
Common stock, $0.001 par value per share, 100,000 shares authorized as of March 31, 2024 and December 31, 2023; 4,906 shares issued and outstanding as of March 31, 2024 and December 31, 2023	5	5
Additional paid-in capital	125,050	124,945
Accumulated deficit	(114,979)	(108,265)
Total stockholders' equity	10,076	16,685
Total liabilities and stockholders' equity	$ 17,018	$ 22,781

About NeuroBo Pharmaceuticals Inc

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

CEO	Mr. Hyung-Heon Kim
WEBSITE	neurobopharma.com
INDUSTRY	Biotechnology
EMPLOYEES	2

NeuroBo Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for NeuroBo Pharmaceuticals Inc? What does NRBO stand for in stocks?

NRBO is the stock ticker symbol of NeuroBo Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of NeuroBo Pharmaceuticals Inc (NRBO)?

As of Fri May 17 2024, market cap of NeuroBo Pharmaceuticals Inc is 23.06 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NRBO stock?

You can check NRBO's fair value in chart for subscribers.

What is the fair value of NRBO stock?

You can check NRBO's fair value in chart for subscribers. The fair value of NeuroBo Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of NeuroBo Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NRBO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is NeuroBo Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether NRBO is over valued or under valued. Whether NeuroBo Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact NeuroBo Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NRBO.